Prostate cancer (PCa) is an incurable disease at the metastatic stage. Although there are different options for treatment, the results are limited. MicroRNAs (miRNAs) are a group of small, noncoding, regulatory RNAs with important roles in regulating gene expression. miR-145 is reported to be a key tumor suppressor miRNA (tsmiR) that controls important oncogenes, such as MYC and RAS. In this study, in vitro studies were performed to show the control of MYC and RAS by miR-145. Flow cytometry was used to analyze cell proliferation and apoptosis. The efficacy of miR-145 in treating metastatic PCa was tested in nude mice using a model of bone metastasis promoted by intraventricular injection of PC-3MLuc-C6 cells. Tumor growth was evaluated by an in vivo bioluminescence system. After the full establishment of metastases on day 21, six animals were treated with three intravenous doses of miR-145 (on days 21, 24 and 27), and six were injected with scramble miRNA as controls. Compared to the controls, tumor growth was significantly reduced in animals receiving miR-145, most importantly on day 7 after the third and last dose of miRNA. After discontinuing the treatment, tumor growth resumed, becoming similar to the group of non-treated animals. A decrease in MYC and RAS expression was observed in all cell lines after treatment with miR-145, although statistical significance was achieved only in experiments with LNCaP and PC3 cell lines, with a decrease in 56% (p = 0.012) and 31% (p = 0.013) of RAS expression, respectively. Our results suggest that miR-145 is a potential molecule to be tested for treatment of metastatic, castration-resistant PCa.
Prostate cancer Metastasis Therapy MicroRNA Molecular biology
This is a preview of subscription content, log in to check access.
We thank Mara Sa Junqueira for support with the animals. We thank Cristina Massocco Sales Gomes and Rodrigo Tannura for technical support with cell cycle assays. We thank Hernandes Faustino Carvalho for important reagents. We thank Jose Pontes Junior and Marcia Kubrusly for the critical reading of this manuscript. This study was supported by São Paulo Research Foundation (FAPESP) grants #2012/21966-8 and #2013/07350-7.
AI: Designed and performed experiments, analyzed data, performed statistical analysis and participated in writing the manuscript. STR: Designed experiments and participated in writing the manuscript. DRM: Performed experiments. NIV: Performed experiments. IAS: Performed experiments. AB: Participated in writing the manuscript. ND: Designed experiments. MS: Designed experiments, analyzed data and participated in writing the manuscript. KRML: Designed experiments, analyzed data and participated in writing the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M et al (2014) An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prostatic Dis 17(4):320–324CrossRefPubMedGoogle Scholar
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L et al (2016) Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 34(18):2098–2106CrossRefGoogle Scholar
Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M et al (2008) The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3(12):e4029CrossRefPubMedPubMedCentralGoogle Scholar
Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K et al (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102(34):12177–12182CrossRefPubMedPubMedCentralGoogle Scholar
Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N et al (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18(1):181–187CrossRefPubMedGoogle Scholar
Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A et al (2011) Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 29(3):265–269CrossRefPubMedGoogle Scholar
Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27(12):1788–1793CrossRefPubMedGoogle Scholar
Schaefer A, Stephan C, Busch J, Yousef GM, Jung K (2010) Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 7(5):286–297CrossRefPubMedGoogle Scholar
Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T et al (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130(3):611–621CrossRefPubMedGoogle Scholar
Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A (2013) The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer 108(12):2573–2581CrossRefPubMedPubMedCentralGoogle Scholar
Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H et al (2013) The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J 280(9):2105–2116CrossRefPubMedGoogle Scholar
Patil PA, Magi-Galluzzi C (2015) MicroRNA in prostate cancer: practical aspects. Histol Histopathol 30(12):1379–1396PubMedGoogle Scholar
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl J Med 358(2):140–151CrossRefPubMedPubMedCentralGoogle Scholar
Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH et al (2013) MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31(6):796–801CrossRefPubMedGoogle Scholar
Leite KR, Reis ST, Viana N, Morais DR, Moura CM, Silva IA et al (2015) Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J Cancer 6(3):292–301CrossRefPubMedPubMedCentralGoogle Scholar
Oudard S, Vano Y (2015) The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma. Curr Opin Urol 25(5):402–410CrossRefPubMedGoogle Scholar
Garcia M, Velez R, Romagosa C, Majem B, Pedrola N, Olivan M et al (2014) Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 113(5b):E164–E177CrossRefGoogle Scholar
Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S et al (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. New Engl J Med 373(18):1733–1747CrossRefPubMedPubMedCentralGoogle Scholar
Wei EY, Hsieh JJ (2015) A river model to map convergent cancer evolution and guide therapy in RCC. Nat Rev Urol 12(12):706–712CrossRefPubMedGoogle Scholar